SAR439459 |
Pan- TGFβ neutralizing antibody |
Advanced Malignant Solid Neoplasm/Metastatic Malignant Solid Neoplasm/Unresectable Malignant Solid Neoplasm |
Phase 1 |
NCT04729725 |
Plasma Cell Myeloma Refractory |
Phase1/Phase 2 |
NCT04643002 |
Advanced Liver Cancers |
Phase1/Phase 2 |
NCT04524871 |
NIS793 |
Fully human anti-TGF-β IgG2 monoclonal antibody |
Metastatic Pancreatic Ductal Adenocarcinoma |
Phase2/Phase 3 |
NCT04390763/NCT04935359
|
Myelofibrosis |
Phase1/Phase 2 |
NCT04097821 |
Myelodysplastic Syndromes |
Phase 1 |
NCT04810611 |
ABBV151 |
Humanized monoclonal antibody inhibitor of GARP- TGF-β1 |
Advanced Solid Tumors Cancer |
Phase 1 |
NCT03821935 |
AVID200 |
Engineered TGF-β ligand trap |
Malignant Solid Tumor |
Phase 1 |
NCT03834662 |
Primary Myelofibrosis/Post-essential Thrombocythemia Myelofibrosis/Post-polycythemia Vera Myelofibrosis |
Phase 1 |
NCT03895112 |
Scleroderma, Diffuse |
Phase 1 |
NCT03831438 |
M7824 (bintrafusp alfa) |
Bifunctional anti-PD-L1/TGF-βRII Trap fusion protein |
Thymic Epithelial Tumor/Recurrent Thymoma/Thymic Cancer |
Phase 2 |
NCT04417660 |
Metastatic Colorectal Cancer/Advanced Solid Tumors With Microsatellite Instability |
Phase1/Phase 2 |
NCT03436563 |
HPV Positive Cancer |
Phase1/Phase 2 |
NCT04432597 |
Urothelial Cancer |
Phase 2 |
NCT04501094 |
Kaposi Sarcoma |
Phase1/Phase 2 |
NCT04303117 |
Urothelial Cancer/Bladder Cancer/Genitourinary Cancer/Urogenital Neoplasms/Urogenital Cancer |
Phase 1 |
NCT04235777 |
Advanced Pancreas Cancer |
Phase1/Phase 2 |
NCT04327986 |
Mesothelioma; Lung |
Phase 2 |
NCT05005429 |
Stage II-III HER2 Positive Breast Cancer |
Phase 1 |
NCT03620201 |
Relapsed Small Cell Lung Cancers |
Phase1/Phase 2 |
NCT03554473 |
Unresectable Stage III Non-Small-Cell Lung Cancer |
Phase 2 |
NCT03840902 |
Advanced Stage Breast Cancer |
Phase 1 |
NCT04296942 |
Prostate Neoplasms |
Phase1/Phase 2 |
NCT04633252 |
Metastatic Triple-Negative Breast Cancer |
Phase 1 |
NCT03579472 |
Advanced Solid Tumors |
Phase1/Phase 2 |
NCT04574583 |
Metastatic Prostate Cancer/Advanced Solid Tumors |
Phase1/Phase 2 |
NCT03493945 |
Advanced HPV Associated Malignancies |
Phase1/Phase 2 |
NCT04287868 |
Metastatic Checkpoint Refractory HPV Associated Malignancies/Microsatellite Stable Colon Cancer (MSS) |
Phase 1/Phase 2 |
NCT04708470 |
Triple-Negative Breast Neoplasms |
Phase 2 |
NCT04489940 |
Small Bowel Cancers/Colorectal Cancers |
Phase 2 |
NCT04491955 |
Esophageal Squamous Cell Carcinoma |
Phase 2 |
NCT04595149 |
Untreated Resectable Non-Small-Cell Lung Cancer |
Phase 2 |
NCT04560686 |
Cancers With Brain Metastases |
Phase1/Phase 2 |
NCT04789668 |
Recurrent Head and Neck Squamous Cell Carcinoma/Second Primary Squamous Cell Carcinoma of the Head and Neck |
Phase1/Phase 2 |
NCT04220775 |
Metastatic or Locally Advanced Urothelial Cancer |
Phase 1 |
NCT04349280 |
Squamous Cell Carcinoma of Head and Neck |
Phase 2 |
NCT04428047 |
Biliary Tract Cancer/Cholangiocarcinoma |
Phase 2 |
NCT04727541 |
Advanced Non-small-Cell Lung Cancer |
Phase 2 |
NCT04396535 |
Locally Advanced or Metastatic Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small-Cell Lung Cancer |
Phase 2 |
NCT04971187 |
GFH018 |
Inhibitor of TGF-βRI |
Advanced Solid Tumor |
Phase1/Phase 2 |
NCT04914286 |
SHR-1701 |
Bifunctional anti-PD-L1/TGF-βRII agent |
Pancreatic Cancer |
Phase1/Phase 2 |
NCT04624217 |
Metastatic or Locally Advanced Solid Tumors |
Phase 1 |
NCT03710265/NCT03774979
|
Advanced Solid Tumors |
Phase1/Phase 2 |
NCT04856774 |
Nasopharyngeal Carcinoma |
Phase 1 |
NCT04282070 |
Advanced Solid Tumors |
Phase 1 |
NCT04324814 |
Metastatic Colorectal Cancer |
Phase2/Phase 3 |
NCT04856787 |
Advanced Solid Tumors and B-cell Lymphomas |
Phase1/Phase 2 |
NCT04407741 |
JS201 |
Recombinant PD-1 monoclonal antibody/TGF-βRII bifunctional fusion protein |
Advanced Malignant Tumors |
Phase 1 |
NCT04956926 |
Small-cell Lung Cancer |
Phase 2 |
NCT04951947 |
TST005 |
Bispecific antibody consisting of a PD-L1 monoclonal antibody (mAb) and a TGF-β trap |
Locally Advanced or Metastatic Cancers/Metastatic Human Papillomavirus-Related Malignant Neoplasm |
Phase 1 |
NCT04958434 |
TASO-001 |
Antisense oligonucleotide against TGF-β2 |
Advanced or Metastatic Solid Tumor |
Phase 1 |
NCT04862767 |
TEW-7197 (Vactosertib) |
TGF-β receptor ALK4/ALK5 inhibitor |
Metastatic Pancreatic Cancer |
Phase1/Phase 2 |
NCT03666832 |
Advanced Stage Solid Tumors |
Phase 1 |
NCT02160106 |
Myeloproliferative Neoplasm |
Phase 2 |
NCT04103645 |
LY2157299 (galunisertib) |
Small molecule antagonist of the tyrosine kinase TGFBR1 |
Nasopharyngeal Carcinoma |
Phase 2 |
NCT04605562 |
LY3200882 |
Inhibitor of TGFβRI |
Solid Tumor |
Phase 1 |
NCT02937272 |
TRK250 |
siRNA-based oligonucleotide selectively suppressing TGFβ1 |
Idiopathic Pulmonary Fibrosis |
Phase 1 |
NCT03727802 |
STP705 |
siRNA-based oligonucleotide selectively suppressing TGFβ1 and COX-2 |
Basal Cell Carcinoma |
Phase 2 |
NCT04669808 |
Bowen's Disease/Cutaneous Squamous Cell Carcinoma in Situ |
Phase1/Phase 2 |
NCT04293679 |
Keloid |
Phase 2 |
NCT04844840 |
Hepatocellular Carcinoma/Liver Metastases/Cholangiocarcinoma |
Phase 1 |
NCT04676633 |
Squamous Cell Carcinoma in Situ |
Phase 2 |
NCT04844983 |
QLS31901 |
PDL1/TGFβ antibody |
Advanced Malignant Tumor |
Phase 1 |
NCT04954456 |
ACE-1334 |
superfamily based ligand trap of TGFβ1 and c3 |
Systemic Sclerosis With and Without Interstitial Lung Disease |
Phase 1/Phase 2 |
NCT04948554 |
ACE-536 (Luspatercept) |
TGFβ superfamily ligand trap |
Myelodysplastic Syndromes |
Phase2/Phase 3 |
NCT04477850/NCT03900715/NCT03682536
|
Myelodysplastic Syndromes/Β-thalassemia/Myeloproliferative Neoplasm-Associated Myelofibrosis |
Phase 3 |
NCT04064060 |
Myeloproliferative Disorders/Myelofibrosis/Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/Anemia |
Phase 3 |
NCT04717414 |
Β-Thalassemia |
Phase 2 |
NCT04143724 |
Primary Myelofibrosis/Post-Polycythemia Vera/Myelofibrosis |
Phase 3 |
NCT03755518 |
NNC0361-0041 |
Recombinant supercoiled plasmid encoding PPI, TGF-β1, IL-10, and IL-2 |
Type I Diabetes |
Phase 1 |
NCT04279613 |
PF-06952229 |
TGFβ1 inhibitor |
Advanced Solid Tumors |
Phase 1 |
NCT03685591 |
GT90001 |
Fully human anti-ALK-1 mAb (IgG2) |
Metastatic Hepatocellular Carcinoma |
Phase1/Phase 2 |
NCT03893695 |
Solid Tumors |
Phase1/Phase 2 |
NCT04984668 |
Trabedersen |
TGFβ2 specific phosphorothioate antisense oligodeoxynucleotide |
COVID-19 |
Phase 2 |
NCT04801017 |